We represented Tennessee Oncology in the launch of OneOncology in affiliation with global private equity firm General Atlantic. OneOncology is a community oncology practice management company. General Atlantic invested $200 million in OneOncology, which is designed to help community oncology practices with technology, data, research and innovation by leveraging its scale as OneOncology affiliates with other practices across the United States. Tennessee Oncology’s physicians are also investors. Flatiron Health serves as OneOncology’s technology and data platform.
Tennessee Oncology is one of the nation’s largest community-based cancer care specialists and home to one of the leading clinical trial networks in the country.
This transaction was named a winner in the “Healthcare and Life Sciences Deal of the Year ($100MM-$1B)” category for the 18th Annual M&A Advisor Awards in 2019. In addition, it had been named a finalist in the “Private Equity Deal of the Year ($100MM-$250MM)” category. Bass, Berry & Sims had six separate deals recognized as finalists among nine categories for the 2019 M&A Advisor Awards.